135 related articles for article (PubMed ID: 15281186)
1. Social contract theory and just decision making: lessons from genetic testing for the BRCA mutations.
Williams-Jones B; Burgess MM
Kennedy Inst Ethics J; 2004 Jun; 14(2):115-42. PubMed ID: 15281186
[TBL] [Abstract][Full Text] [Related]
2. Democratising access to genetic services.
Williams-Jones B; Burgess MM
Fam Cancer; 2006; 5(1):117-21. PubMed ID: 16528615
[TBL] [Abstract][Full Text] [Related]
3. Actor-network theory: a tool to support ethical analysis of commercial genetic testing.
Williams-Jones B; Graham JE
New Genet Soc; 2003 Dec; 22(3):271-96. PubMed ID: 15115034
[TBL] [Abstract][Full Text] [Related]
4. Private genetic testing in Canada: a summary.
Williams-Jones B
Health Law Rev; 2001; 9(3):10-3. PubMed ID: 15706712
[No Abstract] [Full Text] [Related]
5. Direct to confusion: lessons learned from marketing BRCA testing.
Matloff E; Caplan A
Am J Bioeth; 2008 Jun; 8(6):5-8. PubMed ID: 18726769
[TBL] [Abstract][Full Text] [Related]
6. "Be ready against cancer, now": direct-to-consumer advertising for genetic testing.
William-Jones B
New Genet Soc; 2006 Apr; 25(1):89-107. PubMed ID: 17312631
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenetic interventions, orphan drugs, and distributive justice: the role of cost-benefit analysis.
Rai AK
Soc Philos Policy; 2002; 19(2):246-70. PubMed ID: 12678089
[No Abstract] [Full Text] [Related]
8. Impact of gene patents and licensing practices on access to genetic testing for inherited susceptibility to cancer: comparing breast and ovarian cancers with colon cancers.
Cook-Deegan R; DeRienzo C; Carbone J; Chandrasekharan S; Heaney C; Conover C
Genet Med; 2010 Apr; 12(4 Suppl):S15-38. PubMed ID: 20393305
[TBL] [Abstract][Full Text] [Related]
9. European opposition to exclusive control over predictive breast cancer testing and the inherent implications for U.S. patent law and public policy: a case study of the Myriad Genetics' BRCA patent controversy.
Paradise J
Food Drug Law J; 2004; 59(1):133-54. PubMed ID: 15190928
[No Abstract] [Full Text] [Related]
10. Intellectual property and biotechnology: the European debate.
Brody B
Kennedy Inst Ethics J; 2007 Jun; 17(2):69-110. PubMed ID: 18018994
[TBL] [Abstract][Full Text] [Related]
11. Myriad Genetics: In the eye of the policy storm.
Gold ER; Carbone J
Genet Med; 2010 Apr; 12(4 Suppl):S39-70. PubMed ID: 20393310
[TBL] [Abstract][Full Text] [Related]
12. The UK's policy on genetic testing services supplied direct to the public -- two spheres and two tiers.
Holtzman NA
Community Genet; 1998; 1(1):49-52. PubMed ID: 11660582
[No Abstract] [Full Text] [Related]
13. [Federal judge and government of the United States against gene patenting].
Cassier M; Stoppa-Lyonnet D
Med Sci (Paris); 2011; 27(6-7):662-6. PubMed ID: 21718652
[No Abstract] [Full Text] [Related]
14. Human gene patents: the possible impacts on genetic services healthcare.
Walpole IR; Dawkins HJ; Sinden PD; O'Leary PC
Med J Aust; 2003 Aug; 179(4):203. PubMed ID: 12914511
[TBL] [Abstract][Full Text] [Related]
15. The patent is political: the consequences of patenting the BRCA genes in Britain.
Parthasarathy S
Community Genet; 2005; 8(4):235-42. PubMed ID: 16244478
[TBL] [Abstract][Full Text] [Related]
16. Privatization and just healthcare.
Buchanan A
Bioethics; 1995 Jul; 9(3-4):220-39. PubMed ID: 11653038
[TBL] [Abstract][Full Text] [Related]
17. Do patents impede the provision of genetic tests in Australia?
Nicol D; Liddicoat J
Aust Health Rev; 2013 Jun; 37(3):281-5. PubMed ID: 23702081
[TBL] [Abstract][Full Text] [Related]
18. Why even egalitarians should favor market health insurance.
Shapiro D
Soc Philos Policy; 1998; 15(2):84-132. PubMed ID: 11657117
[No Abstract] [Full Text] [Related]
19. Usefulness of Canadian Public Health Insurance Administrative Databases to Assess Breast and Ovarian Cancer Screening Imaging Technologies for BRCA1/2 Mutation Carriers.
Larouche G; Chiquette J; Plante M; Pelletier S; Simard J; Dorval M
Can Assoc Radiol J; 2016 Nov; 67(4):308-312. PubMed ID: 27318890
[TBL] [Abstract][Full Text] [Related]
20. Marginal medicine.
Lamm RD
JAMA; 1998 Sep; 280(10):931-3. PubMed ID: 9739981
[No Abstract] [Full Text] [Related]
[Next] [New Search]
